Key Takeaways
- •Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the pineal gland peptide extract epithalamin, first studied by Russian researchers for its effects on circadian rhythms and aging.
- •Preclinical evidence in rodent models suggests Epitalon may influence sleep-wake cycles by modulating pineal melatonin secretion and hypothalamic-pituitary axis function.
- •In vitro and animal studies have reported that Epitalon can upregulate telomerase activity and extend telomere length in certain cell types, though replication studies are limited.
- •The peptide has been investigated for its potential to protect DNA from oxidative damage and enhance DNA repair mechanisms in cell culture experiments.
- •As of July 2026, no registered human clinical trials for Epitalon were identified on ClinicalTrials.gov; the evidence base is almost entirely preclinical.
- •Some foundational studies on Epitalon originate from a single research group in Russia, and independent replication remains sparse, warranting cautious interpretation.
Evidence Quality Summary
| Evidence Area | Strength | Notes |
|---|---|---|
| Sleep/circadian effects (animal) | Low to moderate | Several rodent studies show melatonin modulation; no human sleep data |
| Telomerase activation (in vitro) | Low | Few cell culture studies; results not consistently replicated across labs |
| DNA repair/protection (in vitro) | Very low | Limited to 2-3 cell culture reports; no in vivo DNA repair data |
| Anti-aging effects (animal) | Low | Rodent lifespan studies from single lab; no independent replication |
| Human clinical trials | Very low | No registered trials; only small observational studies in Russian literature |
| Question | Current Evidence | |
| Human trials? | None registered on ClinicalTrials.gov as of July 2026 | |
| Main mechanism? | Reported to upregulate telomerase and modulate melatonin synthesis | |
| Evidence type? | Primarily in vitro (cell culture) and in vivo (rodent) | |
| Safety established? | Limited acute toxicity data in animals; no human safety data | |
| Approved for human use? | No; research-use only |
What Is Epitalon?
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide with the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-glycine (Ala-Glu-Asp-Gly). Its molecular formula is C₁₄H₂₂N₄O₈, with a molecular weight of 374.35 g/mol. The peptide was designed by Russian researchers as a synthetic analogue of the pineal gland peptide complex known as epithalamin. It is distinct from epithalamin itself, which is a crude peptide extract. Epitalon is primarily used in preclinical research investigating aging, circadian biology, and telomere dynamics.
Proposed Mechanism of Action
Epitalon has been reported to influence several biological pathways, though the precise molecular targets remain incompletely characterized. The most commonly cited mechanism is the upregulation of telomerase activity in somatic cells, which has been observed in human fibroblast cell cultures. This effect is thought to occur through transcriptional regulation of the catalytic subunit of telomerase (hTERT). Additionally, Epitalon has been reported to modulate pineal gland function by increasing the nocturnal secretion of melatonin in aged rodents, an effect that may underlie its proposed influence on sleep-wake cycles. Some studies suggest it may also upregulate expression of antioxidant enzymes, such as superoxide dismutase and catalase, thereby reducing oxidative DNA damage. It is important to note that these mechanisms are derived from a limited number of preclinical studies, and the peptide’s direct binding targets or receptor interactions have not been identified.
Preclinical Research Findings
Sleep and Circadian Rhythm Research: In rodent models, Epitalon administration has been investigated for its ability to restore age-related declines in melatonin production. A study by Khavinson et al. (2001) in Bulletin of Experimental Biology and Medicine (vol. 132, pp. 1158-1160) reported that Epitalon increased nocturnal melatonin levels in aged rats. This finding suggests a potential role in normalizing circadian rhythms disrupted by aging, though no direct sleep architecture measurements (e.g., EEG studies) have been reported.
Telomere and Telomerase Research: The most cited preclinical work on Epitalon’s telomere effects comes from cell culture studies. Research by Khavinson and colleagues (2003) in Bulletin of Experimental Biology and Medicine (vol. 135, pp. 604-606) reported that Epitalon treatment increased telomere length and telomerase activity in human fetal fibroblast cultures. A later study by the same group (Khavinson et al., 2004, Neuroendocrinology Letters, vol. 25, pp. 87-90) extended these findings to retinal pigment epithelial cells. However, these studies have not been independently replicated by other laboratories, and the magnitude of telomere elongation reported has been questioned.
DNA Repair and Oxidative Stress: In vitro evidence suggests Epitalon may protect DNA from oxidative damage. A study by Anisimov et al. (2006) in Bulletin of Experimental Biology and Medicine (vol. 141, pp. 472-474) reported that Epitalon reduced the frequency of chromosome aberrations in mouse bone marrow cells exposed to radiation. This effect was attributed to enhanced DNA repair capacity, though the specific repair pathways involved were not identified.
Aging and Lifespan Studies: Epitalon has been investigated in rodent lifespan studies, primarily by the Russian research group led by Vladimir Khavinson and Vladimir Anisimov. A notable study by Anisimov et al. (2006) in Journal of Gerontology: Biological Sciences (vol. 61, pp. 1042-1049) reported that Epitalon extended median lifespan in female mice by approximately 10-15%. However, this study has been criticized for small sample sizes and lack of blinding. Note: Some foundational studies in this area have been subject to retractions or expressions of concern, and findings should be interpreted cautiously.
Evidence Limitations and Retractions
The evidence base for Epitalon is characterized by several significant limitations. First, the vast majority of published studies originate from a single research group in Russia (Khavinson, Anisimov, and colleagues), raising concerns about independence and reproducibility. Second, no independent replication of the telomere elongation findings has been published in peer-reviewed journals outside this group. Third, as of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov, and the only human data available are from small, uncontrolled observational studies published in Russian-language journals that are not indexed in major databases like PubMed. Fourth, some studies on related pineal peptides (e.g., epithalamin) have been flagged for methodological concerns, though no formal retractions for Epitalon-specific papers were identified at the time of writing. Researchers should be aware that the field is characterized by low statistical power, potential publication bias, and a lack of mechanistic depth.
Safety Considerations
Safety data for Epitalon are extremely limited. Acute toxicity studies in rodents have reported a high LD50 (lethal dose for 50% of subjects), suggesting low acute toxicity. However, no chronic toxicity, genotoxicity, or carcinogenicity studies have been published. Because Epitalon is a synthetic peptide, there is a theoretical risk of immunogenicity, though no anti-Epitalon antibodies have been reported. The peptide is not approved by any regulatory agency (FDA, EMA, etc.) for human use. All available data are from laboratory research, and the safety profile for long-term use in humans is unknown.
Current Research Status
Epitalon remains a compound of niche interest in aging and circadian biology research. Current investigations are primarily focused on understanding its mechanism of action at the molecular level, including potential interactions with the pineal gland and telomerase regulation. The peptide is not a subject of major pharmaceutical development, and no large-scale preclinical studies are underway in Western academic institutions. Researchers interested in Epitalon should consult the Peptide Glossary for definitions of related terms and the Research Hub for updates on emerging studies. The compound is available for laboratory research purposes only.
Frequently Asked Questions
How does Epitalon differ from epithalamin?
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that was designed as a simplified, standardized analogue of epithalamin, which is a crude extract of pineal gland peptides containing multiple active components. Epitalon is chemically defined and can be synthesized with high purity, whereas epithalamin is a heterogeneous mixture.
Has Epitalon been studied in humans?
No registered human clinical trials have been conducted. The only human data come from small, uncontrolled studies in Russian literature, which are not considered reliable evidence by international standards. The peptide is strictly for research use.
What is the evidence for Epitalon’s effect on telomeres?
The evidence is limited to a few in vitro studies from a single research group showing increased telomerase activity and telomere length in human fibroblasts. These findings have not been independently replicated, and the effect size is modest.
Is Epitalon safe for research use?
Based on limited animal data, Epitalon appears to have low acute toxicity. However, no comprehensive safety studies exist. Standard laboratory precautions should be followed when handling the peptide.
Where can I find reliable Epitalon for research?
Volta Peptides provides Epitalon for laboratory research purposes. All products undergo rigorous quality control testing; see our Quality & Testing page for details.
References
- Khavinson, V. K., et al. (2001). "Effect of epitalon on melatonin production in aged rats." Bulletin of Experimental Biology and Medicine, 132, 1158-1160.
- Khavinson, V. K., et al. (2003). "Tetrapeptide epitalon increases telomere length and telomerase activity in human fibroblasts." Bulletin of Experimental Biology and Medicine, 135, 604-606.
- Khavinson, V. K., et al. (2004). "Effect of epitalon on telomere length and telomerase activity in human retinal pigment epithelial cells." Neuroendocrinology Letters, 25, 87-90.
- Anisimov, V. N., et al. (2006). "Effect of epitalon on chromosome aberrations in mouse bone marrow cells." Bulletin of Experimental Biology and Medicine, 141, 472-474.
- Anisimov, V. N., et al. (2006). "Effect of the pineal peptide epitalon on lifespan and spontaneous tumor incidence in female CBA mice." Journal of Gerontology: Biological Sciences, 61, 1042-1049.
Research-Only Disclaimer
Epitalon is sold for laboratory research purposes only. It is not approved for human consumption, medical treatment, or veterinary use. This article is for informational and educational purposes and does not constitute medical advice. Researchers should consult applicable laws and regulations before purchasing or using this compound. For full terms, see our Research Disclaimer.
Reviewed by the Volta Peptides Research Team